Table 4.

Cytotoxicity of compounds 19‒47 toward human cancer cell lines.

Compd.	GP (%) a
	MCF-7		HeLa		HCT-116
	10 µM	100 µM	10 µM	100 µM	10 µM	100 µM
19	88 ± 2	87 ± 2	100 ± 2	76 ± 2	100 ± 2	92 ± 3
20	88 ± 3	82 ± 2	90 ± 4	71 ± 2	101 ± 2	93 ± 2
21	94 ± 3	84 ± 3	97 ± 2	92 ± 1	93 ± 6	84 ± 6
22	91 ± 4	77 ± 7	91 ± 6	65 ± 7	86 ± 7	68 ± 5
23	93 ± 2	77 ± 2	87 ± 4	89 ± 6	86 ± 6	75 ± 3
24	93 ± 5	91 ± 5	97 ± 1	91 ± 1	91 ± 6	76 ± 4
25	97 ± 5	87 ± 5	94 ± 3	79 ± 6	84 ± 5	81 ± 6
26	97 ± 2	93 ± 6	98 ± 2	91 ± 1	85 ± 6	92 ± 5
27	82 ± 5	44 ± 5	22 ± 2	7 ± 0.6	63 ± 4	15 ± 1
28	96 ± 4	82 ± 4	100 ± 2	92 ± 3	86 ± 8	71 ± 2
29	95 ± 4	81 ± 4	87 ± 2	87 ± 3	74 ± 0.4	79 ± 1
30	93 ± 7	81 ± 1	95 ± 5	91 ± 1	85 ± 4	82 ± 2
31	93 ± 6	85 ± 6	95 ± 2	95 ± 4	86 ± 7	70 ± 4
32	96 ± 2	89 ± 3	100 ± 2	92 ± 4	89 ± 7	86 ± 5
33	93 ± 8	71 ± 3	100 ± 2	93 ± 3	86 ± 5	83 ± 5
34	86 ± 7	62 ± 0.4	96 ± 4	95 ± 5	92 ± 6	69 ± 6
35	89 ± 7	82 ± 4	98 ± 5	92 ± 4	84 ± 7	76 ± 2
36	93 ± 4	73 ± 0.1	101 ± 0.1	95 ± 1	93 ± 7	72 ± 7
37	95 ± 3	72 ± 0.5	99 ± 1	91 ± 4	91 ± 5	85 ± 5
38	95 ± 3	81 ± 0.8	98 ± 4	95 ± 2	99 ± 7	83 ± 4
39	94 ± 9	65 ± 5	99 ± 1	72 ± 5	94 ± 2	65 ± 2
40	93 ± 4	86 ± 8	99 ± 0.5	98 ± 0.5	96 ± 4	89 ± 2
41	100 ± 1	61 ± 0.1	100 ± 1	86 ± 3	92 ± 3	69 ± 2
42	89 ± 3	79 ± 2	98 ± 2	99 ± 0.2	92 ± 1	90 ± 4
43	95 ±5	81 ± 6	101 ± 3	95 ± 5	89 ± 5	83 ± 5
44	92 ± 6	66 ± 4	98 ± 1	43 ± 3	93 ± 4	40 ± 4
45	100 ± 3	76 ± 1	97 ± 3	18 ± 1	92 ± 7	61 ± 2
46	96 ± 5	79 ± 4	100 ± 2	80 ± 3	89 ± 6	84 ± 2
47	92 ± 4	46 ± 5	100 ± 2	9 ± 0.8	91 ± 4	18 ± 2

^a Growth percent (GP) was measured at concentrations 1, 10, 25, 50 and 100 µM. Two representative doses were shown, i.e., 10 µM and 100 µM. Values are expressed as the mean ± SD of at least three independent experiments.